EP 60

Cracking the Undruggable Target

Scientists have been trying to crack the code of a notoriously undruggable target in pancreatic cancer for 40 years. Recently, a revolutionary drug called Deraxanracib has shown promising results in clinical trials, offering new hope for patients. This episode delves into the science behind this breakthrough and its potential implications for precision medicine.

pancreatic cancerRAS proteinDeraxanracibcyclophilin Amolecular glueprecision medicine

play_arrowListen to episode

Key Concepts

RAS Protein

The RAS protein is a binary molecular switch that regulates cellular growth and division.
In cancer, the RAS protein is often mutated, leading to uncontrolled cell growth and tumor proliferation.

Deraxanracib

Deraxanracib is a macrocyclic small molecule that works by hijacking cyclophilin A to build a custom boot that clamps over the RAS mutation.
The drug has shown significant clinical results in patients with metastatic pancreatic cancer, including a 60% reduction in the risk of death.

Cyclophilin A

Cyclophilin A is a natural chaperone protein that helps to fold and stabilize other proteins.
Deraxanracib hijacks cyclophilin A to build a custom boot that clamps over the RAS mutation.

Molecular Glue

Molecular glue refers to the ability of a drug to bind to a protein and alter its function.
Deraxanracib works by using cyclophilin A as a molecular glue to build a custom boot that clamps over the RAS mutation.

Precision Medicine

Precision medicine refers to the use of targeted therapies to treat specific diseases or conditions.
Deraxanracib is an example of a precision medicine approach, as it targets the RAS mutation in pancreatic cancer.

Episode Summary

check_circleThe RAS protein is a key driver of pancreatic cancer, but its smooth surface has made it difficult to target with traditional drugs.
check_circleDeraxanracib works by hijacking a natural chaperone protein called cyclophilin A to act as a molecular glue, building a custom boot that clamps over the RAS mutation.
check_circleThis approach has shown significant clinical results, including a 60% reduction in the risk of death and a doubling of median overall survival in patients with metastatic pancreatic cancer.
check_circleThe drug's success has been attributed to its ability to outsmart the cancer's evolutionary mechanisms, which have historically allowed it to develop resistance to other treatments.
check_circleResearchers are now exploring combination therapies that pair Deraxanracib with other targeted drugs to block the cancer's escape routes and prevent resistance.
check_circleThe discovery of Deraxanracib's mechanism has opened up new possibilities for treating other undruggable diseases, such as Alzheimer's and autoimmune disorders.

Full Transcript

Discussion

Join the discussion — sign in to leave a comment.